Table 1.
Selected characteristics of interest among eight randomized controlled trials examining statin-associated type 2 diabetes risk.
| Study characteristics | Participant characteristics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Studies | Mean length of follow-up (years) |
Study sample size |
Year of baseline data |
Method to define T2D |
% Women |
% Caucasian |
Mean age (years) |
Mean BMI (kg/m2) |
Mean LDL- C levels (mg/dL) |
Mean FPG Levels (mg/dL) |
| Downs (1998) | 5.2 | 6605 | 1993 | T2D diagnosis, T2D medication use, and FPG >126mg/dL |
15.1 | 89 | 58 | 26.7 | 150 | R |
| Freeman (2001) | 4.8 | 6595 | 1990 | T2D medication use, FPG >126mg/dL |
0.0 | 100 | 55 | 25.9 | 193.3 | 86.5 |
| Furberg (2002) | 4.8 | 10355 | 1994 | FPG >126mg/dL |
49 | 41 | 66.4 | 29.9 | 146 | 122.1 |
| Shepherd (2002) | 3.2 | 5804 | 1999 | T2D medication use, FPG >126mg/dL |
51.7 | 100 | 75.3 | 26.8 | 146.9 | 92.5 |
| Sever (2003) | 3.3 | 10341 | 1999 | FPG >126mg/dL |
18.8 | 94 | 63.2 | 28.7 | 131.5 | 111.7 |
| Nakamura (2006) | 5.3 | 7832 | 1999 | 12D diagnosis, T2D medication use, and FPG >126mg/dL |
68.0 | 0 | 59 | 23.9 | 156 | 109.1 |
| Ridker (2008) | 1.9 | 17802 | 2007 | T2D diagnosis, T2D medication use, and FPG >126mg/dL |
38.2 | 71.3 | 66 | 28.4 | 108 | 94 |
| Yusuf(2016) | 5.6* | 12705 | 2010 | T2D diagnosis, T2D medication use, and FPG >126mg/dL |
46.7 | 20 | 65.8 | 27.1 | 128.6 | 95.4* |
| 8 studies (1998–2016) | 4.3 | 9754.9 | 1998 | 35.9 | 64.4 | 63.6 | 27.2 | 145.0 | 101.6 | |
BMI = Body mass index
LDL-C = Low-density lipoprotein
FPG = Fasting plasma glucose
R = Data requested, but not available
*
= Median values